

RESEARCH

Open Access

Tetradecylthioacetic acid inhibits proliferation of human SW620 colon cancer cells - gene expression profiling implies endoplasmic reticulum stress

Anne G Lundemo^{1†}, Caroline HH Pettersen^{1†}, Kjetil Berge^{2†}, Rolf K Berge² and Svanhild A Schønberg^{1*}

Abstract

Background: Previous reports have shown an antiproliferative effect of the synthetic, 3-thia fatty acid tetradecylthioacetic acid (TTA) on different cancer cells *in vitro* and *in vivo*. The mechanisms behind the observed effects are poorly understood. We therefore wanted to explore the molecular mechanisms involved in TTA-induced growth inhibition of the human colon cancer cell line SW620 by gene expression profiling.

Methods: An antiproliferative effect of TTA on SW620 cells *in vitro* was displayed in real time using the xCELLigence System (Roche). Affymetrix gene expression profiling was performed to elucidate the molecular mechanisms behind the antiproliferative effect of TTA. Changes in gene expression were verified at protein level by western blotting.

Results: TTA reduced SW620 cell growth, measured as baseline cell index, by 35% and 55% after 48 h and 72 h, respectively. We show for the first time that TTA induces an endoplasmic reticulum (ER) stress response in cancer cells. Gene expression analysis revealed changes related to ER stress and unfolded protein response (UPR). This was verified at protein level by phosphorylation of eukaryote translation initiation factor 2 alpha (eIF2 α) and downstream up-regulation of activating transcription factor 4 (ATF4). Transcripts for positive and negative cell cycle regulators were down- and up-regulated, respectively. This, together with a down-regulation of Cyclin D1 at protein level, indicates inhibition of cell cycle progression. TTA also affected transcripts involved in calcium homeostasis. Moreover, mRNA and protein level of the ER stress inducible C/EBP-homologous protein (CHOP), Tribbles homolog 3 (Drosophila) (TRIB3) and CCAAT/enhancer binding protein beta (C/EBP β) were enhanced, and the C/EBP β LIP/LAP ratio was significantly increased. These results indicate prolonged ER stress and a possible link to induction of cell death.

Conclusion: We find that TTA-induced growth inhibition of SW620 cells seems to be mediated through induction of ER stress and activation of the UPR pathway.

Keywords: Cell cycle, Colon cancer, Docosahexaenoic acid, Endoplasmic reticulum stress, Gene expression analysis, Phosphorylated eIF2 α , Tetradecylthioacetic acid, Thia fatty acids, Unfolded protein response

Background

Colon cancer is one of the most common incident cancers across Europe [1]. There is an urgent need for finding novel, alternative or supplementary cancer treatments. Polyunsaturated fatty acids (PUFAs) are able

to inhibit growth of both colon and several other types of cancer cells *in vitro* and *in vivo* ([2-5] and reviewed in [6-8]). During the last two decades, chemical modified fatty acid (FA) analogs have been produced in an attempt to achieve FAs having increased metabolic stability and more selective and targeted effects (reviewed in [9]). Among these is the bioactive, saturated 3-thia FA tetradecylthioacetic acid (TTA). TTA has been shown to have both a cardioprotective effect, as well as an antiproliferative effect on cancer cells (reviewed in

* Correspondence: svanhild.schonberg@ntnu.no

† Contributed equally

¹Norwegian University of Science and Technology, Faculty of Medicine, Department of Laboratory Medicine, Children's and Women's Health, PO Box 8905, N-7491 Trondheim, Norway

Full list of author information is available at the end of the article

[10]). TTA has been found to inhibit growth of glioma [11,12], leukemia [13-16] and colon cancer cell lines [11,17] *in vitro* and *in vivo*, and hepatoma [18] and breast cancer cells [19] *in vitro*. TTA seems to be more potent in reducing cell growth compared with the omega-3 (n-3) PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) [20]. A diet containing TTA has also resulted in increased vascularisation of colon cancer xenografts in mice [17] and improved the survival of mice having leukemia xenografts [11,14]. TTA food supplementation seems to be generally well tolerated by healthy persons [15,21], and TTA therefore may have a potential in cancer treatment alone or in combination with other therapies.

The structure of TTA is equal to the saturated palmitic acid (PA), except that TTA has a sulphur atom inserted at the third position in the carbon chain [19]. The sulphur atom makes TTA resistant to mitochondrial β -oxidation and probably contributes substantially to its biological effects (reviewed in [10]). TTA is capable of reducing the growth of cancer cells that are not growth inhibited by PA [17,20,22]. TTA is degraded relatively slowly to various dicarboxylic acids via ω -oxidation and sulphur oxidation in the endoplasmic reticulum (ER) and subsequent β -oxidation in the peroxisomes. Except from blocked mitochondrial β -oxidation, the chemical properties and metabolism of TTA resembles those of normal FAs. TTA is activated by binding to coenzyme A and incorporated into various lipids, especially phospholipids (reviewed in [10,23]).

Before any recommendations regarding use of TTA in cancer treatment can be given, it's important to elucidate the molecular mechanisms underlying the growth inhibitory effect of TTA. In some, but not all, cancer cells, TTA inhibits cancer cell growth via increased lipid peroxidation and oxidative stress [12], or partly via activation of peroxisome proliferator activated receptor gamma [22]. Also, TTA has been shown to induce apoptosis in several glioma [12,13] and leukemia cell lines [13,14]. Induction of apoptosis seems to be related to effects on mitochondria. TTA can induce a decrease in mitochondrial membrane potential [13,24] and lead to release of cytochrome C (cyt C) and a reduction in mitochondrial glutathione, the latter indicating a selective modulation of the mitochondrial redox equilibrium [13]. Most of the biological effects of TTA assumed to be implicated in mediating the inhibitory effect of TTA on cancer cells do not seem to be specific for TTA, since they also are assumed to be involved in the growth inhibitory effect of other FAs like n-3 PUFAs [25-27].

We have previously shown that TTA inhibits the growth of SW620 human colon cancer cells *in vitro* and *in vivo* [17]. SW620 cell growth is also inhibited by n-3 PUFAs [2,4]. By using gene expression analysis, we

found that DHA induces extensive changes in the expression of transcripts involved in biological pathways like ER stress and unfolded protein response (UPR), protein degradation, Ca^{2+} homeostasis, cell cycle progression and apoptosis [28]. Others have found that PA also can induce ER stress in human [29] and rat cancer cells [30].

The main functions of ER are protein synthesis and folding, lipid synthesis and maintenance of Ca^{2+} homeostasis. Disruption of these processes causes accumulation of misfolded proteins in ER lumen, leading to ER stress and activation of the cellular stress response UPR. The purpose of UPR is to restore cell homeostasis and promote cell survival, but during prolonged ER stress, apoptosis may be activated. During ER stress, one of the three ER stress sensors; eukaryotic translation initiation factor 2 alpha (eIF2 α) kinase 3 (EIF2AK3/PERK) is known to phosphorylate eIF2 α , thereby attenuating global protein synthesis to reduce the protein load of ER. Reduced synthesis of e.g. cyclin D1 promotes cell cycle arrest, creating time to cope with the stress. However, translation of certain mRNAs is allowed, like mRNAs for activating transcription factor 4 (ATF4) and its downstream target C/EBP-homologous protein (CHOP) [31,32]. CHOP, which is also regulated by X-box binding protein 1 (XBP-1) (reviewed in [33]), promotes apoptosis by down-regulating anti-apoptotic factors like B-cell lymphoma 2 (Bcl-2) [34] and up-regulating pro-apoptotic factors like the Bcl-2-interacting protein Bim [35].

During ER stress XBP-1 also activates the transcription factor CCAAT/enhancer binding protein beta (C/EBP β) [36], which participates in regulation of differentiation, cell growth, cell survival and apoptosis [37,38]. Human C/EBP β is mainly expressed as two 46 and 42 kDa liver enriched activator protein isoforms (LAP and LAP*) and a 20 kDa liver enriched inhibitor protein isoform (LIP) [39], which are synthesized from different AUG start codons within the C/EBP β mRNA [40]. Since LIP lacks a transcription activation domain [41] and suppresses the transactivation by LAP, the LIP/LAP ratio influences on the extent of C/EBP β -activated transcription [40].

LIP has been shown to decrease during early ER stress, and increase during prolonged ER stress, causing an increase in the LIP/LAP ratio [42]. Increased LIP seems to be essential for CHOP-induced apoptosis, since heterodimerization of LIP with CHOP promotes nuclear translocation of CHOP and pro-apoptotic gene regulation by CHOP [43]. In addition, CHOP-C/EBP β [44] and CHOP-ATF4 [45] heterodimeres up-regulate the pro-apoptotic pseudo-kinase Tribbles homolog 3 (*Drosophila*) (TRIB3), which can promote apoptosis by inhibiting the anti-apoptotic kinase Akt [46] and the

transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) [47]. CHOP- and TRIB3-promoted cell death might be accompanied by the ER stress-induced caspase 4 (CASP4) and calpains [32,48,49].

In this report we have used Affymetrix gene expression analysis to search for possible molecular mechanisms underlying the growth inhibitory effect of TTA on SW620 cells *in vitro*. The results indicate that TTA reduces SW620 cell growth through activation of ER stress and UPR, by a similar mechanism as observed after treatment with DHA [28].

Results

TTA reduces growth of SW620 cells

In accordance with previous results [17], we verified a growth inhibitory effect of TTA (75 μ M) on SW620 colon cancer cells by cell counting (data not shown) and by measuring the growth real time by using the xCELLigence System (Roche) (Figure 1A). The SW620 growth curve, which is presented as baseline cell index, showed that TTA (75 μ M) significantly reduced the baseline cell index by 35% and 55% after 48 h and 72 h, respectively, compared to the control (Figure 1B).

TTA induces extensive changes at mRNA level indicating ER stress and UPR

In an attempt to unravel the mechanisms underlying the growth-inhibiting effect of TTA, SW620 cells were cultivated in the absence or presence of 75 μ M TTA for 24 h, followed by gene expression profiling. Differentially

expressed transcripts are presented and listed by full and short names in Table 1 and Additional file 1.

After incubation with TTA, the transcription level of several genes involved in ER stress and UPR were affected. The ER stress sensors inositol-requiring enzyme 1 (IRE1) and activating transcription factor 6 (ATF6), and downstream targets of these, like XBP-1, were up-regulated (Table 1). However, most changes in the ER stress signaling pathway were found downstream of PERK. Phosphorylation of eIF2 α by PERK is a hallmark of ER stress (reviewed in [31]). After TTA treatment, phosphorylated eIF2 α (eIF2 α -P) was found significantly increased after 6 h and 24 h (Figure 2A).

Phosphorylation of eIF2 α induces transcription of ATF4 and its downstream targets, like ATF3, CHOP, growth arrest and DNA-damage-inducible 34 (GADD34), TRIB3 [50,51] and heme oxygenase 1 (HMOX1) [52]. All these transcripts were up-regulated upon TTA treatment (Table 1). Moreover, the protein levels of ATF4, CHOP (Figure 2A) and TRIB3 (Figure 2B) were also increased. ATF4 is known to induce genes involved in amino acid synthesis, and several transcripts involved in amino acid synthesis and transport were also up-regulated (Table 1 and Additional file 1).

When UPR is activated, cells try to up-regulate the folding capacity e.g. through up-regulation of chaperones and heat shock proteins (Hsps) [31]. Transcripts of the folding machinery were found to be up-regulated in the SW620 cells after incubation with TTA. These include prefoldin 2 (PFDN2), DnaJ (HSP40) homolog, subfamily B, member 2 (DNAJB2), DNAJB14, DnaJ




Table 1 Gene expression results

Gene Symbol	Affymetrix ID	Refseq NCBI ID	Transcript name	SW620 Fold Change 24 h
ER stress and unfolded protein response				
ATF3	202672_s_at	NM_001030287 NM_001040619 NM_001674 NM_004024	Activating transcription factor 3	3.5
ATF4	200779_at	NM_001675 NM_182810	Activating transcription factor 4	1.7
ATF6	217550_at 231927_at 203952_at	NM_007348	Activating transcription factor 6	1.5 1.3 1.2
CEBPB	212501_at	NM_005194	CCAAT/enhancer binding protein (C/EBP), beta	3.2
CHOP/DDIT3	209383_at	NM_001130101 NM_001130102 NM_004083 NM_005693	DNA-damage-inducible transcript 3	2.7
GADD34	37028_at 202014_at	NM_014330	Growth arrest and DNA-damage-inducible 34	2.0 2.0
IRE1/ERN1	235745_at	NM_001433	Inositol-requiring enzyme 1/Endoplasmic reticulum to nucleus signaling 1	1.7
NRF2/NFE2L2	201146_at	NM_001145412 NM_001145413 NM_006164	Nuclear factor (erythroid-derived 2)-like 2	1.3
TRIB3	155788_a_at 218145_at	NM_021158	Tribbles homolog 3 (Drosophila)	5.1 4.9
XBP1	242021_at 200670_at	NM_001079539 NM_005080	X-box binding protein 1	1.2 1.6
Chaperones/Protein folding/Unfolded protein response/Protein degradation/Amino acid synthesis				
ASNS	205047_s_at	NM_001673 NM_133436 NM_183356	Asparagine synthetase	4.8
CREB3L2	212345_s_at	NM_194071	cAMP responsive element binding protein 3-like 2	1.4
CREB3L3	234361_at	NM_032607	cAMP responsive element binding protein 3-like 3	3.0
DNAJB2	202500_at	NM_001039550 NM_006736	DnaJ (Hsp40) homolog, subfamily B, member B2	1.3
DNAJB14	222850_s_at	NM_001031723	DnaJ (Hsp40) homolog, subfamily B, member B14	1.2
DNAJC24	242562_at	NM_181706	DnaJ (Hsp40) homolog, subfamily C, member 24	1.4
EDEM1	203279_at	NM_014674	ER degradation enhancer, mannosidase alpha-like 1	1.3
EDEM3	220342_x_at	NM_025191	ER degradation enhancer, mannosidase alpha-like 3	1.2
ERO1LB	231944_at	NM_019891	ERO1-like beta (<i>S. cerevisiae</i>)	1.3
HMOX1/HSP32	203665_at	NM_002133	Heme oxygenase (decycling) 1	1.6
HSPA13	202557_at 202558_s_at	NM_006948	Heat shock 70kDa protein 13	1.4 1.7
PDIA2	206691_s_at	NM_006849	Protein disulfide isomerase family A, member 2	1.2
PFDN2	218336_at	NM_012394	Prefoldin 2	1.4
PSMB1	214289_at	NM_002793	Proteasome subunit, beta type, 1	1.3
SQSTM1	201471_s_at 213112_s_at 239004_at 244804_at	NM_001142298 NM_001142299 NM_003900	Sequestosome 1	2.1 3.1 1.3 2.1
UBE2B	239163_at	NM_003337	Ubiquitin-conjugating enzyme E2B (RAD6 homolog)	1.5
SEC61A2	219499_at 228747_at	NM_001142627 NM_001142628 NM_018144	Sec61 alpha 2 subunit (<i>S. cerevisiae</i>)	1.3 1.2

Table 1 Gene expression results (Continued)

SEC61B	244700_at	NM_006808	Sec61 beta subunit	1.6
SEC63	201914_s_at 201915_s_at 201916_s_at	NM_007214	SEC63 homolog (S. cerevisiae)	1.3 1.2 1.3
Ca²⁺ homeostasis, signaling and transport				
ATP2B4/PMCA4	205410_s_at 212135_s_at 212136_at	NM_001001396 NM_001684	ATPase, Ca ²⁺ transporting, plasma membrane 4	1.5 2.7 5.4
CAPN1	232012_at	NM_005186	Calpain 1, (mu/l) large subunit	1.4
CAPN2	208683_at 214888_at	NM_001146068 NM_001748	Calpain 2, large subunit	1.4 1.8
CAPN5	205166_at	NM_004055	Calpain 5	1.4
HERPUD1	217168_s_at	NM_001010989 NM_001010990 NM_014685	Homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1	1.9
ITPR1	244090_at	—	Inositol 1,4,5-triphosphate receptor, type 1	1.3
ITPR3	201187_s_at 201188_s_at 201189_s_at	NM_002224	Inositol 1,4,5-triphosphate receptor, type 3	1.3 1.5 1.5
PLCD3	234971_x_at 1552476_s_at	NM_133373	Phospholipase C, delta 3	1.3 1.3
S100A10	200872_at 238909_at	NM_002966	S100 calcium binding protein A10	1.2 2.4
S100P	204351_at	NM_005980	S100 calcium binding protein P	4.9
STC2	203438_at 203439_s_at	NM_003714	Stanniocalcin 2	2.1 2.7
Cell cycle/ Apoptosis				
ATF5	204998_s_at 204999_s_at	NM_012068	Activating transcription factor 5	1.5 1.7
AURKA	208080_at	NM_003600 NM_198433 NM_198434 NM_198435 NM_198436 NM_198437	Aurora kinase A	-1.3
BIRC5	202094_at 202095_s_at 210334_x_at	NM_001012270 NM_001012271 NM_001168	Baculoviral IAP repeat-containing 5/Survivin	-1.7 -1.3 -1.3
CASP4	213596_at	NM_001225 NM_033306	Caspase 4	1.4
CCNA2	203418_at 213226_at	NM_001237	Cyclin A2	-1.2 -1.2
CCND3	201700_at	NM_001136017 NM_001136125 NM_001136126 NM_001760	Cyclin D3	-2.0
CCNE1	213523_at	NM_001238 NM_057182	Cyclin E1	-1.3
CCNE2	205034_at 211814_s_at	NM_057749	Cyclin E2	-2.9 -3.1
CCNF	204827_s_at	NM_001761	Cyclin F	-1.2
CDC2/CDK1	203214_x_at	NM_001130829 NM_001786 NM_033379	Cell division cycle 2, G1 to S and G2 to M	-1.2
CDK2	204252_at 211804_s_at	NM_001798 NM_052827	Cyclin-dependent kinase 2	-1.3 -1.4

Table 1 Gene expression results (Continued)

CDK4	202246_s_at	NM_000075	Cyclin-dependent kinase 4	-1.4
CDK5	204247_s_at	NM_001164410 NM_004935	Cyclin-dependent kinase 5	-1.5
CDK6	224847_at 224848_at 224851_at 243000_at	NM_001145306 NM_001259	Cyclin-dependent kinase 6	-1.4 -1.5 -1.3 -1.3
CDKN2A	211156_at	NM_000077 NM_058195 NM_058197	Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)	1.3
CDKN2B	207530_s_at 236313_at	NM_004936 NM_078487	Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)	1.5 2.0
CDKN2D	210240_s_at	NM_001800 NM_079421	Cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4)	1.2
CUL1	238509_at	NM_003592	Cullin 1	1.4
KLF4	220266_s_at 221841_s_at	NM_004235	Kruppel-like factor 4 (gut)	1.9 2.4
PDCD4	202731_at 212593_s_at	NM_014456 NM_145341	Programmed cell death 4 (neoplastic transformation inhibitor)	1.3 1.3
PDCD6	222152_at 222380_s_at	NM_013232	Programmed cell death 6	1.3 1.3
SFN	33322_i_at 33323_r_at 209260_at	NM_006142	Stratifin	1.6 1.7 1.6

Significantly differentially expressed transcripts in SW620 treated with TTA (75 μ M) for 24 h as determined by Affymetrix microarray analysis ($P < 0.05$).

(Hsp40) homolog, subfamily C, member 24 (DNAJC24), heat shock protein 13 (HSPA13), HSP32 (HMOX1) and hypoxia up-regulated 1 (HYOU1) (Table 1 and Additional file 1). Protein disulfide isomerase family A, member 2 (PDIA2) and ERO1-like beta (ERO1LB), which are known to catalyze protein folding [31,53], were also up-regulated (Table 1). However, some DnaJ (Hsp40) homolog subfamily members and Hsps were also found to be down-regulated (Additional file 1).

During ER stress, improperly folded proteins are transferred to ER degradation enhancer, mannosidase alpha-like protein (EDEM) and translocated to cytosol for proteasomal degradation; a process called ER associated degradation (ERAD) [31]. EDEM1 and EDEM3, in addition to several proteasomal subunits and ubiquitin-related transcripts, were up-regulated upon TTA treatment. Also, proteasome subunit, beta type, 1 (PSMB1), ubiquitin-conjugating enzyme E2B (RAD6 homolog) (UBE2B) and cullin1 (CUL1) were up-regulated (Table 1 and Additional file 1). In addition, TTA also up-regulated sequestosome 1 (SQSTM1), which is able to sequester and shuttle polyubiquitinated, misfolded proteins to the proteasome (reviewed in [54]) (Table 1). Moreover, TTA up-regulated transcripts for parts of the ER translocation machinery which transports proteins to the cytosol, like Sec61 alpha 2 subunit (SEC61A2), Sec61 beta subunit (SEC61B) and SEC63 homolog (SEC63) (Table 1).


TTA affects Ca^{2+} homeostasis

Another indication of an ER stress condition in SW620 cells treated with TTA is the altered expression of transcripts coding for proteins involved in Ca^{2+} homeostasis. The more than 5-fold up-regulation of ATPase, Ca^{2+} -transporting, plasma membrane 4 (ATP2B4/PMCA4) might indicate the presence of a high Ca^{2+} concentration in the cytosol (Table 1). A possible high Ca^{2+} level in the cytosol may be part of the ER stress response, with Ca^{2+} leaking from ER through the up-regulated IP3 receptors, type 1 and 3 (ITPR1 and 3, Table 1). We also found Phospholipase C D3 (PLCD3), which is known to participate in the generation of IP3 [55], to be up-regulated at mRNA level after TTA-treatment (Table 1).

Among other important Ca^{2+} -related transcripts, we found several S100 Ca^{2+} binding proteins to be differentially expressed after TTA-treatment, e.g. S100P and S100A10 were up-regulated (Table 1 and Additional file 1). Also, TTA caused up-regulation of Stanniocalcin 2 (STC2), which is induced downstream of PERK and critical for survival after UPR [56]. TTA further up-regulated homocysteine-inducible endoplasmic reticulum stress-inducible ubiquitin-like domain member 1 (HERPUD1) (Table 1), which is known to counteract Ca^{2+} disturbances during ER stress [57].

Effect of TTA on cell cycle

TTA affected the mRNA level of several cell cycle transcripts, most of them having rather small fold change



values. Positive cell cycle regulators were down-regulated and negative regulators were up-regulated, as outlined below.

The cell cycle is known to be positively regulated by cyclins (CCNs) and cyclin dependent kinases (CDKs). The mRNA level of cyclin D3 (CCND3), but not cyclin D1, was down-regulated upon TTA treatment (Table 1). However, the protein level of cyclin D1 was significantly decreased after incubation with TTA (Figure 2A). Moreover, transcripts for CCNA2, CCNE1, CCNE2, CCNF, CDK1/CDC2, CDK2, CDK4, CDK5 and CDK6 were down-regulated (Table 1), indicating inhibition of cell cycle progression. The CDK4 inhibitors CDK inhibitor 2A (CDKN2A), CDKN2B and CKDN2D, which are negative regulators of cell cycle, were increased (Table 1). In addition, the tumor suppressor programmed cell death 4 (PDCD4), which is able to reduce the protein level of CDK4 [58], and PDCD6 were up-regulated (Table 1).

Other important cell cycle related transcripts that were up-regulated by TTA were ATF5, stratifin (SFN/14-3-3 sigma) and kruppel like factor 4 (KLF4) (Table 1). TTA also induced down-regulation of aurora kinase A (AURKA) and survivin/baculoviral IAP repeat-containing 5 (BIRC5) (Table 1).

TTA changes expression of transcripts involved in ER stress-related apoptosis

Transcripts related to ER stress-induced apoptosis were also up-regulated upon TTA treatment. In addition to the up-regulation of CHOP and TRIB3, TTA also increased transcription of CASP4, calpain 1, large subunit (CAPN1), CAPN2 and CAPN5 (Table 1).

The C/EBPβ LIP isoform is known to augment ER stress-induced cell death by interfering with the expression of TRIB3 [59]. C/EBPβ (CEBPB) was up-regulated 3.2-fold at mRNA level (Table 1) after TTA treatment.

Western blotting mainly displayed two C/EBP β isoforms; a highly expressed 45 kDa LAP isoform and a lower expressed 20 kDa LIP isoform. The 42 kDa LAP* isoform was only found in very low amounts (Figure 2B). TTA did not affect the level of LAP, but induced a significant 6.9- and 11.2-fold induction of LIP after 24 and 48 h, respectively (Figure 2B). The accumulation of LIP at these time points caused a significant 6.6- and 13.3-fold increase in the LIP/LAP ratio after 24 h and 48 h, respectively, compared to control cells.

During ER stress, cAMP responsive element binding protein 3-like 2 and 3 (CREB3L2 and CREB3L3) are induced in order to attenuate ER stress-induced cell death [60]. These transcripts were also up-regulated (Additional file 1).

Discussion

Several studies have shown that TTA inhibits the growth of various cancer cells *in vitro* and *in vivo* [13,20,22]. We have previously shown that TTA inhibits DNA synthesis in SW620 human colon cancer cells in a time- and dose-dependent manner [17], and the growth inhibitory effect of TTA on this cell line was confirmed in the current study by xCELLigence proliferation assay. This assay monitors cell growth real time by measuring changes in electric impedance between two golden electrodes embedded in the bottom of the cell culture wells. The impedance, which is converted to a cell index value, is directly proportional to the number of cells and also reflects the cells' viability, morphology and adhesion strength [61]. The baseline cell index declined compared to the control from approximately 20 hours after TTA-supplementation. Previous studies have indicated that TTA affects multiple biochemical pathways that might play a role in its growth-limiting effect on different cancer cells. However, the exact mechanisms are not yet clear.

This is the first study demonstrating that TTA is able to induce ER stress in cancer cells. Transcripts involved in ER stress and downstream of all three ER stress sensors, like ATF6, IRE1, XBP-1 and ATF4, were found to be differentially expressed after treating SW620 cells with TTA. Also, the increased expression of Hsps and DNAs indicates that the cells try to increase their protein folding capacity. The up-regulation of EDEM1 and EDEM3, SQSTM1, proteasomal subunits and ubiquitin-related transcripts indicates activation of ERAD.

The PERK branch of UPR was found to be activated, supported by the increased protein level of eIF2 α -P and ATF4, as well as up-regulation of several downstream targets of ATF4, like ATF3, ASNS, CHOP and TRIB3, at mRNA level. CHOP and TRIB3, also induced at protein level, are known to link ER stress to ER stress-induced cell death (reviewed in [32]). The enhanced

level of these proteins and transcripts for CASP4 and calpains indicates that TTA causes prolonged ER stress and direct the cell fate towards induction of death. We have previously shown that DHA induces ER stress with increased eIF2 α -P, ATF4 and CHOP in the same cell line [28,62]. We also found HL-60 leukemia cells to induce ER stress upon EPA treatment [63].

In SW620 cells, TTA up-regulated the C/EBP β LIP isomer, while LAP was unchanged. LIP is capable of modulating the ER stress response by augmenting cell death, e.g. by enhancing the activity of CHOP [43]. On the contrary, LAP may attenuate ER stress and ER stress induced cell death by inhibiting CHOP [59,64]. However, Li *et al.* found that LAP modulated the ER stress response by enhancing the expression of pro-apoptotic genes. They also proposed that the ER stress response may be modulated by regulation of the LIP/LAP ratio [42]. We found this ratio to be increased after 24 and 48 h of TTA treatment, supporting the assumption that TTA causes prolonged ER stress and a switch towards induction of cell death. Even if C/EBP β mRNA was up-regulated, we only found an increase of LIP at protein level. Different regulation of LIP and LAP might be explained by different synthesis and degradation rates of these isomers [42].

Our results also indicate that TTA affects several transcripts involved in cell cycle progression. Transcripts involved in regulation of both the G1/S and G2/M phases were differentially expressed. In general, positive cell cycle regulators (like CDKs, cyclins, AURKA and survivin) were down-regulated, and negative cell cycle regulators (like ATF5, SFN and KLF4) were up-regulated, which indicates a stop in the cell cycle progression. We have previously demonstrated that DHA treatment of the SW620 cells affects several cell cycle transcripts and proteins like CDKs, cyclins and survivin etc. [62] and arrests the cells in the G2/M phase of the cell cycle [2]. Brewer *et al.* stated that cell cycle arrest might be induced during ER stress to prevent cells from completing cell division when the conditions are compromising proper folding and assembly of proteins [65].

TTA also seems to induce changes in expression of transcripts involved in maintenance of Ca²⁺ homeostasis. The ER lumen contains a high Ca²⁺ concentration, and induction of ER stress may either come from and/or culminate with a release of Ca²⁺ from the ER (reviewed in [66,67]). ER stress-accompanied changes in the Ca²⁺ metabolism may lead to a pro-apoptotic signal via the mitochondria [66]. We have previously shown that DHA and EPA affect Ca²⁺ homeostasis in cancer cells [28,63]. Apoptosis has been observed in other cancer cells treated with TTA [13,22], and it has been proposed that this effect is mediated via mitochondrial alterations, such as decrease in mitochondrial membrane

potential and release of Cyt C [13]. CHOP and C/EBP β may be involved in the regulation of mitochondrial stress genes like TRIB3 [44] in response to accumulation of unfolded proteins in mitochondria [68]. Their up-regulation by TTA may indicate that the SW620 cells are undergoing a mitochondrial stress after TTA treatment.

Madsen *et al.* found TTA to be incorporated mainly into phospholipids in liver after TTA supplementation to rats [69]. The inner mitochondrial membrane phospholipid cardiolipin (CL) is essential for the function of several mitochondrial protein complexes. It interacts with mitochondrial Cyt C, which might utilize reactive oxygen species and cause oxidation of CL. Oxidized CL is required for release of pro-apoptotic factors like Cyt C to cytosol [70]. Enrichment of EPA and DHA in CL isolated from colonic mucosa in rats fed fish oil or EPA/DHA ethyl esters might result in high susceptibility to lipid peroxidation due to the FAs' high degree of unsaturation. This may trigger release of pro-apoptotic factors from mitochondria (reviewed in [71]). Decreased synthesis of CL has also been related to Cyt C release from mitochondria during PA-induced apoptosis (reviewed in [9]). It remains to be investigated if this is the case with TTA.

Conclusions

TTA induces extensive changes in the expression of genes involved in several biological pathways. TTA causes accumulation of misfolded proteins in ER, causing ER stress and activation of UPR. The results show that TTA inhibits SW620 cell growth, at least partly, via the same mechanisms as DHA. Thus, cancer cells seem to cope with stress induced by various FAs through the same mechanisms.

Methods

Materials and cell culture

TTA was prepared at the Department of Chemistry, University of Bergen, Norway, as described previously [72] and in Supplementary experimental procedures (Additional file 2). All other solvents were of reagent grade from commercial sources. Antibody specifications are found in Additional file 2. The human colon carcinoma cell line SW620 was obtained from the American Type Culture Collection (ATCC, Rockville, MD) and cultivated in Leibovitz's L-15 medium (Cambrex, Bio-Whittaker, Walkersville, MD) supplemented with L-glutamine (2 mM), FBS (10%) and gentamicin (45 mg/l) (complete growth medium), in a humidified atmosphere of 5% CO₂: 95% air at 37°C.

Cell proliferation assay by xCELLigence

SW620 cells were seeded in 16 well plates (E-plate 16, Roche, Mannheim, Germany) (12.000 cells in 150 μ l

medium/well), following the xCELLigence Real Time Cell Analyzer (RTCA) DP instrument manual as provided by the manufacturer (Roche). After ~24 h, TTA (75 μ M, prepared as described in Additional file 2) or the vehicle NaOH (control medium) was added, and the experiment was allowed to run for 72 h. Average baseline cell index and percent reduction of baseline cell index for TTA-treated cells compared to control cells were calculated for at least two measurements from 4 replicate experiments \pm SD. Significance was calculated using one-tailed Student's t-test ($P < 0.05$).

RNA isolation, gene expression profiling and statistical analysis

SW620 cells were seeded in 175 cm² flasks (3.5×10^6 cells in 28 ml medium). After 24 h incubation, cells were treated with TTA (75 μ M) or NaOH (control) for 24 h. Cell harvesting and total RNA isolation was performed as elaborated in [28], using the High Pure RNA Isolation Kit (Roche). Gene expression profiling was performed following the Eukaryote expression manual from Affymetrix (Santa Clara, CA), using the Human Genome U133 2.0 Plus Array (Affymetrix), as described in Additional file 2. Statistical analysis of gene expression results was performed using the RMA method. Differentially expressed genes were identified using a linear model with a modified T-statistic [73], and results were corrected for multiple testing using the method described in [74] with a false discovery rate of 0.05. Annotations of probe sets and biological information of genes were retrieved from the web-based NetAffx Analysis Center at affymetrix.com and eGOn at genetools.no. Signal values presented are mean values of 3 replicate experiments. All experiments have been submitted to Array-Express with accession number E-MEXP-2590.

Western blot analysis

Cells were treated with TTA (75 μ M) or NaOH for 3, 6, 12, 24 and/or 48 h, as described in the gene expression profiling method. For detection of eIF2 α -P and cyclin D1, cells were harvested as elaborated in [28], and cytosolic protein extracts were prepared immediately in lysis buffer as described in [63]. Nuclear protein extracts for detection of ATF4, CHOP, TRIB3 and C/EBP β were obtained by using Nuclear Extract Kit (Active Motif, Rixensart, Belgium) according to the manufacturer's protocol. Protein concentrations were measured using Bio-Rad Protein Assay (Bio-Rad, Hercules, CA), and the protein extracts were snap-frozen in liquid nitrogen and stored at -80°C until further use. Cytosolic and nuclear proteins (80 or 50 μ g per well, respectively) were separated on 10% precast denaturing NuPAGE[®] gels (Invitrogen, Carlsbad, US) and transferred onto Immobilon polyvinylidene difluoride membranes

(Millipore, Billerica, MA). Membranes were blocked in phosphate buffered saline buffer with 0.1% (v/v) Tween[®] 20 (BioRad, Hercules, CA) and 5% blocker non-fat dry milk, before incubated with primary and secondary horse radish peroxidase-conjugated antibodies (DAKO, Carpinteria, CA) dissolved in this blocking buffer as described in Additional file 2. eIF2 α -P incubations were performed using tris-buffered saline Tween 20 buffer as described in [63]. Blots were detected by chemiluminescence using SuperSignal[®] West Femto Maximum Sensitivity Substrate (Pierce, Rockford, IL) and visualized by Kodak Image Station 4000R (Eastman Kodak Co., Rochester, NY). Western blot band intensities were quantified using Kodak Molecular Imaging Software (version 4.0.1). Quantified western blot results, based on 3 independent replicates, were analysed as described in the proliferation assay method.

Additional material

Additional file 1: Supplementary gene expression results. Functional categories of significantly differentially expressed transcripts affected in SW620 cells treated with TTA (75 μ M) for 24 h, as determined by Affymetrix microarray analysis ($P < 0.05$).

Additional file 2: Supplementary experimental procedures. The file contains supplementing information about the experimental procedures including preparation of TTA stock solution and medium, gene expression experiments and antibodies used.

List of abbreviations

Transcript short names are to be found in Table 1 and Additional file 1. Cyt C: Cytochrome C; DHA: Docosahexaenoic acid; eIF2 α : Eukaryote translation initiation factor 2 alpha; EIF2AK3/PERK: eIF2 α kinase 3; eIF2 α -P: phosphorylated eIF2 α ; EPA: Eicosapentaenoic acid; ER: Endoplasmic reticulum; ERAD: ER-associated degradation; FAs: Fatty acids; Hsps: Heat shock proteins; LAP: Liver enriched activator protein; LIP: Liver enriched inhibitor protein; n-3: Omega-3; PA: Palmitic acid; PUFAs: Polyunsaturated fatty acids; TTA: Tetradecylthioacetic acid; UPR: Unfolded protein response

Acknowledgements

The authors gratefully acknowledge Endre Anderssen, Norwegian Microarray Consortium (NMC), Norwegian University of Science and Technology (NTNU), Trondheim, Norway for microarray statistical analysis. The work was supported by The Faculty of Medicine, NTNU, The Cancer Research Fund, The Research Council of Norway through grants from the Functional Genomics Program (FUGE) and grants from Helse Vest, Norway. Microarray experiments were performed at the microarray core facility at the Norwegian Microarray Consortium (NMC), Trondheim, which is supported by the FUGE, The Norwegian Research Council.

Mailing address for reprints:

Svanhild A. Schonberg, Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, N-7006, Trondheim, Norway.

Author details

¹Norwegian University of Science and Technology, Faculty of Medicine, Department of Laboratory Medicine, Children's and Women's Health, PO Box 8905, N-7491 Trondheim, Norway. ²Institute of Medicine, Section of Medical Biochemistry, Haukeland University Hospital, University of Bergen, N-5021 Bergen, Norway.

Authors' contributions

AGL carried out cell experiments, xCELLigence experiments, western blots and helped to draft the manuscript. CHHP carried out cell experiments, gene expression experiments and drafted the manuscript. KB participated in study design, carried out initial experiments and helped to draft the manuscript. RKB participated in study design. SAS participated in study design and coordination and helped to draft the manuscript. All authors have read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests. Rolf K Berge and Kjetil Berge have stocks in Thia Medica AS. There is no conflict of interest.

Received: 19 September 2011 Accepted: 25 October 2011

Published: 25 October 2011

References

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: **Estimates of the cancer incidence and mortality in Europe in 2006.** *Ann Oncol* 2007, **18**(3):581-592.
2. Schonberg SA, Lundemo AG, Fladvad T, Holmgren K, Bremseth H, Nilsen A, Gederaas O, Tvedt KE, Egeberg KW, Krokan HE: **Closely related colon cancer cell lines display different sensitivity to polyunsaturated fatty acids, accumulate different lipid classes and downregulate sterol regulatory element-binding protein 1.** *FEBS J* 2006, **273**(12):2749-2765.
3. Finstad HS, Myhrstad MC, Heimli H, Lomo J, Blomhoff HK, Kolset SO, Drevon CA: **Multiplication and death-type of leukemia cell lines exposed to very long-chain polyunsaturated fatty acids.** *Leukemia* 1998, **12**(6):921-929.
4. Bathen TF, Holmgren K, Lundemo AG, Hjelstuen MH, Krokan HE, Griibbestad IS, Schonberg SA: **Omega-3 fatty acids suppress growth of SW620 human colon cancer xenografts in nude mice.** *Anticancer Res* 2008, **28**(6A):3717-3723.
5. Schonberg SA, Rudra PK, Noding R, Skorpen F, Bjerve KS, Krokan HE: **Evidence that changes in Se-glutathione peroxidase levels affect the sensitivity of human tumour cell lines to n-3 fatty acids.** *Carcinogenesis* 1997, **18**(10):1897-1904.
6. Roynette CE, Calder PC, Dupertuis YM, Pichard C: **n-3 polyunsaturated fatty acids and colon cancer prevention.** *Clin Nutr* 2004, **23**(2):139-151.
7. Cockbain AJ, Toogood GJ, Hull MA: **Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer.** *Gut* 2011.
8. Rose DP, Connolly JM: **Omega-3 fatty acids as cancer chemopreventive agents.** *Pharmacol Ther* 1999, **83**(3):217-244.
9. Tronstad KJ, Berge K, Berge RK, Bruserud O: **Modified fatty acids and their possible therapeutic targets in malignant diseases.** *Expert Opin Ther Targets* 2003, **7**(5):663-677.
10. Berge RK, Skorve J, Tronstad KJ, Berge K, Gudbrandsen OA, Grav H: **Metabolic effects of thia fatty acids.** *Curr Opin Lipidol* 2002, **13**(3):295-304.
11. Berge K, Tronstad KJ, Abdi-Dezfuli F, Ranheim T, Mahesparan R, Bjerkvig R, Berge RK: **Poorly oxidizable fatty acid analogues inhibit the proliferation of cancer cells in culture.** *Adv Exp Med Biol* 1999, **466**:205-210.
12. Tronstad KJ, Berge K, Dyroy E, Madsen L, Berge RK: **Growth reduction in glioma cells after treatment with tetradecylthioacetic acid: changes in fatty acid metabolism and oxidative status.** *Biochem Pharmacol* 2001, **61**(6):639-649.
13. Tronstad KJ, Gjertsen BT, Krakstad C, Berge K, Brustugun OT, Doskeland SO, Berge RK: **Mitochondrial-targeted fatty acid analog induces apoptosis with selective loss of mitochondrial glutathione in promyelocytic leukemia cells.** *Chem Biol* 2003, **10**(7):609-618.
14. Iversen PO, Sorensen DR, Tronstad KJ, Gudbrandsen OA, Rustan AC, Berge RK, Drevon CA: **A bioactively modified fatty acid improves survival and impairs metastasis in preclinical models of acute leukemia.** *Clin Cancer Res* 2006, **12**(11 Pt 1):3525-3531.
15. Tronstad KJ, Bruserud O, Berge K, Berge RK: **Antiproliferative effects of a non-beta-oxidizable fatty acid, tetradecylthioacetic acid, in native human acute myelogenous leukemia blast cultures.** *Leukemia* 2002, **16**(11):2292-2301.
16. Erikstein BS, McCormack E, Tronstad KJ, Schwede F, Berge R, Gjertsen BT: **Protein kinase A activators and the pan-PPAR agonist tetradecylthioacetic acid elicit synergistic anti-leukaemic effects in AML through CREB.** *Leuk Res* 2010, **34**(1):77-84.

17. Jensen LR, Berge K, Bathen TF, Wergedahl H, Schonberg SA, Bofin A, Berge RK, Gribbestad IS: Effect of dietary tetradecylthioacetic acid on colon cancer growth studied by dynamic contrast enhanced MRI. *Cancer Biol Ther* 2007, **6**(11):1810-1816.
18. Sorensen HN, Norheim L, Spydevold O, Gautvik KM: Uptake and receptor binding of dexamethasone in cultured 7800 C1 hepatoma cells in relation to regulation of cell growth and peroxisomal beta-oxidation. *Int J Biochem* 1990, **22**(10):1171-1177.
19. Abdi-Dezfuli F, Berge RK, Rasmussen M, Thorsen T, Aakvaag A: Effects of saturated and polyunsaturated fatty acids and their 3-thia fatty acid analogues on MCF-7 breast cancer cell growth. *Ann N Y Acad Sci* 1994, **744**:306-309.
20. Abdi-Dezfuli F, Froyland L, Thorsen T, Aakvaag A, Berge RK: Eicosapentaenoic acid and sulphur substituted fatty acid analogues inhibit the proliferation of human breast cancer cells in culture. *Breast Cancer Res Treat* 1997, **45**(3):229-239.
21. Pettersen RJ, Salem M, Skorve J, Ulvik RJ, Berge RK, Nordrehaug JE: Pharmacology and safety of tetradecylthioacetic acid (TTA): phase-1 study. *J Cardiovasc Pharmacol* 2008, **51**(4):410-417.
22. Berge K, Tronstad KJ, Flindt EN, Rasmussen TH, Madsen L, Kristiansen K, Berge RK: Tetradecylthioacetic acid inhibits growth of rat glioma cells *ex vivo* and *in vivo* via PPAR-dependent and PPAR-independent pathways. *Carcinogenesis* 2001, **22**(11):1747-1755.
23. Skrede S, Sorensen HN, Larsen LN, Steineger HH, Hovik K, Spydevold OS, Horn R, Bremer J: Thia fatty acids, metabolism and metabolic effects. *Biochim Biophys Acta* 1997, **1344**(2):115-131.
24. Berge K, Tronstad KJ, Bohov P, Madsen L, Berge RK: Impact of mitochondrial beta-oxidation in fatty acid-mediated inhibition of glioma cell proliferation. *J Lipid Res* 2003, **44**(1):118-127.
25. Noding R, Schonberg SA, Krokan HE, Bjerne KS: Effects of polyunsaturated fatty acids and their n-6 hydroperoxides on growth of five malignant cell lines and the significance of culture media. *Lipids* 1998, **33**(3):285-293.
26. Calviello G, Serini S, Piccioni E, Pessina G: Antineoplastic effects of n-3 polyunsaturated fatty acids in combination with drugs and radiotherapy: preventive and therapeutic strategies. *Nutr Cancer* 2009, **61**(3):287-301.
27. Edwards IJ, O'Flaherty JT: Omega-3 Fatty Acids and PPAR γ in Cancer. *PPAR Research* 2008, **2008**:1-14.
28. Jakobsen CH, Storvold GL, Bremseth H, Follstad T, Sand K, Mack M, Olsen KS, Lundemo AG, Iversen JG, Krokan HE, et al: DHA induces ER stress and growth arrest in human colon cancer cells: associations with cholesterol and calcium homeostasis. *J Lipid Res* 2008, **49**(10):2089-2100.
29. Gu X, Li K, Laybutt DR, He ML, Zhao HL, Chan JC, Xu G: Bip overexpression, but not CHOP inhibition, attenuates fatty-acid-induced endoplasmic reticulum stress and apoptosis in HepG2 liver cells. *Life Sci* 2010, **87**(23-26):724-732.
30. Wei Y, Wang D, Pagliassotti MJ: Saturated fatty acid-mediated endoplasmic reticulum stress and apoptosis are augmented by trans-10, cis-12-conjugated linoleic acid in liver cells. *Mol Cell Biochem* 2007, **303**(1-2):105-113.
31. Schroder M, Kaufman RJ: ER stress and the unfolded protein response. *Mutat Res* 2005, **569**(1-2):29-63.
32. Szegezdi E, Logue SE, Gorman AM, Samali A: Mediators of endoplasmic reticulum stress-induced apoptosis. *EMBO Rep* 2006, **7**(9):880-885.
33. Oyadomari S, Mori M: Roles of CHOP/GADD153 in endoplasmic reticulum stress. *Cell Death Differ* 2004, **11**(4):381-389.
34. McCullough KD, Martindale JL, Klotz LO, Aw TY, Holbrook NJ: Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. *Mol Cell Biol* 2001, **21**(4):1249-1259.
35. Puthalakath H, O'Reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND, Hughes PD, Michalak EM, McKimm-Breschkin J, Motoyama N, et al: ER stress triggers apoptosis by activating BH3-only protein Bim. *Cell* 2007, **129**(7):1337-1349.
36. Chen C, Dudenhausen EE, Pan YX, Zhong C, Kilberg MS: Human CCAAT/enhancer-binding protein beta gene expression is activated by endoplasmic reticulum stress through an unfolded protein response element downstream of the protein coding sequence. *J Biol Chem* 2004, **279**(27):27948-27956.
37. Piwien Pilipuk G, Galigniana MD, Schwartz J: Subnuclear localization of C/EBP beta is regulated by growth hormone and dependent on MAPK. *J Biol Chem* 2003, **278**(37):35668-35677.
38. Smink JJ, Leutz A: Rapamycin and the transcription factor C/EBPbeta as a switch in osteoclast differentiation: implications for lytic bone diseases. *J Mol Med* 2010, **88**(3):227-233.
39. Baldwin BR, Timchenko NA, Zahnow CA: Epidermal growth factor receptor stimulation activates the RNA binding protein CUG-BP1 and increases expression of C/EBPbeta-LIP in mammary epithelial cells. *Mol Cell Biol* 2004, **24**(9):3682-3691.
40. Descombes P, Schibler U: A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. *Cell* 1991, **67**(3):569-579.
41. Poli V, Mancini FP, Cortese R: IL-6DBP, a nuclear protein involved in interleukin-6 signal transduction, defines a new family of leucine zipper proteins related to C/EBP. *Cell* 1990, **63**(3):643-653.
42. Li Y, Bevilacqua E, Chiribau CB, Majumder M, Wang C, Croniger CM, Snider MD, Johnson PF, Hatzoglou M: Differential control of the CCAAT/enhancer-binding protein beta (C/EBPbeta) products liver-enriched transcriptional activating protein (LAP) and liver-enriched transcriptional inhibitory protein (LIP) and the regulation of gene expression during the response to endoplasmic reticulum stress. *J Biol Chem* 2008, **283**(33):22443-22456.
43. Chiribau C-B, Gaccioli F, Huang CC, Yuan CL, Hatzoglou M: Molecular symbiosis of CHOP and C/EBP beta isoform LIP contributes to endoplasmic reticulum stress-induced apoptosis. *Mol Cell Biol* 2010, **30**(14):3722-3731.
44. Ishikawa F, Akimoto T, Yamamoto H, Araki Y, Yoshie T, Mori K, Hayashi H, Nose K, Shibamura M: Gene expression profiling identifies a role for CHOP during inhibition of the mitochondrial respiratory chain. *J Biochem* 2009, **146**(1):123-132.
45. Ohoka N, Yoshii S, Hattori T, Onozaki K, Hayashi H: TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death. *EMBO J* 2005, **24**(6):1243-1255.
46. Du K, Herzig S, Kulkarni RN, Montminy M: TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. *Science* 2003, **300**(5625):1574-1577.
47. Wu M, Xu LG, Zhai Z, Shu HB: SINK is a p65-interacting negative regulator of NF-kappaB-dependent transcription. *J Biol Chem* 2003, **278**(29):27072-27079.
48. Hitomi J, Katayama T, Eguchi Y, Kudo T, Taniguchi M, Koyama Y, Manabe T, Yamagishi S, Bando Y, Imaizumi K, et al: Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Abeta-induced cell death. *J Cell Biol* 2004, **165**(3):347-356.
49. Matsuzaki S, Hiratsuka T, Kuwahara R, Katayama T, Tohyama M: Caspase-4 is partially cleaved by calpain via the impairment of Ca²⁺ homeostasis under the ER stress. *Neurochem Int* 2010, **56**(2):352-356.
50. Ron D, Walter P: Signal integration in the endoplasmic reticulum unfolded protein response. *Nat Rev Mol Cell Biol* 2007, **8**(7):519-529.
51. Schroder M: Endoplasmic reticulum stress responses. *Cell Mol Life Sci* 2008, **65**(6):862-894.
52. He CH, Gong P, Hu B, Stewart D, Choi ME, Choi AM, Alam J: Identification of activating transcription factor 4 (ATF4) as an Nrf2-interacting protein. Implication for heme oxygenase-1 gene regulation. *J Biol Chem* 2001, **276**(24):20858-20865.
53. Pagani M, Fabbri M, Benedetti C, Fassio A, Pilati S, Bulleid NJ, Cabibbo A, Sita R: Endoplasmic reticulum oxidoreductin 1-beta (ERO1-Lbeta), a human gene induced in the course of the unfolded protein response. *J Biol Chem* 2000, **275**(31):23685-23692.
54. Seibenhener ML, Geetha T, Wooten MW: Sequestosome 1/p62—more than just a scaffold. *FEBS Lett* 2007, **581**(2):175-179.
55. Noh DY, Shin SH, Rhee SG: Phosphoinositide-specific phospholipase C and mitogenic signaling. *Biochim Biophys Acta* 1995, **1242**(2):99-113.
56. Ito D, Walker JR, Thompson CS, Moroz I, Lin W, Veselits ML, Hakim AM, Fienberg AA, Thinakaran G: Characterization of stanniocalcin 2, a novel target of the mammalian unfolded protein response with cytoprotective properties. *Mol Cell Biol* 2004, **24**(21):9456-9469.
57. Chigurupati S, Wei Z, Belal C, Vandermeij M, Kyriazis GA, Arumugam TV, Chan SL: The homocysteine-inducible endoplasmic reticulum stress protein counteracts calcium store depletion and induction of CCAAT enhancer-binding protein homologous protein in a neurotoxin model of Parkinson disease. *J Biol Chem* 2009, **284**(27):18323-18333.

58. Jansen AP, Camalier CE, Colburn NH: **Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis.** *Cancer Res* 2005, **65**(14):6034-6041.
59. Meir O, Dvash E, Werman A, Rubinstein M: **C/EBP-beta regulates endoplasmic reticulum stress-triggered cell death in mouse and human models.** *PLoS One* 2010, **5**(3):e9516.
60. Kondo S, Saito A, Hino S, Murakami T, Ogata M, Kanemoto S, Nara S, Yamashita A, Yoshinaga K, Hara H, et al: **BBF2H7, a novel transmembrane bZIP transcription factor, is a new type of endoplasmic reticulum stress transducer.** *Mol Cell Biol* 2007, **27**(5):1716-1729.
61. Abassi YA, Xi B, Zhang W, Ye P, Kirstein SL, Gaylord MR, Feinstein SC, Wang X, Xu X: **Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects.** *Chem Biol* 2009, **16**(7):712-723.
62. Slagsvold JE, Pettersen CHH, Storvold GL, Follestad T, Krokan HE, Schonberg SA: **DHA alters expression of target proteins of cancer therapy in chemoresistant SW620 colon cancer cells.** *Nutr Cancer* 2010, **62**(5):611-621.
63. Slagsvold JE, Pettersen CH, Follestad T, Krokan HE, Schonberg SA: **The antiproliferative effect of EPA in HL60 cells is mediated by alterations in calcium homeostasis.** *Lipids* 2009, **44**(2):103-113.
64. Abreu MM, Sealy L: **The C/EBPbeta isoform, liver-inhibitory protein (LIP), induces autophagy in breast cancer cell lines.** *Exp Cell Res* 2010, **316**(19):3227-3238.
65. Brewer JW, Hendershot LM, Sherr CJ, Diehl JA: **Mammalian unfolded protein response inhibits cyclin D1 translation and cell-cycle progression.** *Proc Natl Acad Sci USA* 1999, **96**(15):8505-8510.
66. Xu C, Bailly-Maitre B, Reed JC: **Endoplasmic reticulum stress: cell life and death decisions.** *J Clin Invest* 2005, **115**(10):2656-2664.
67. Verkhratsky A, Toescu EC: **Endoplasmic reticulum Ca(2+) homeostasis and neuronal death.** *J Cell Mol Med* 2003, **7**(4):351-361.
68. Zhao Q, Wang J, Levichkin IV, Stasinopoulos S, Ryan MT, Hoogenraad NJ: **A mitochondrial specific stress response in mammalian cells.** *EMBO J* 2002, **21**(17):4411-4419.
69. Madsen L, Froyland L, Grav HJ, Berge RK: **Up-regulated delta 9-desaturase gene expression by hypolipidemic peroxisome-proliferating fatty acids results in increased oleic acid content in liver and VLDL: accumulation of a delta 9-desaturated metabolite of tetradecylthioacetic acid.** *J Lipid Res* 1997, **38**(3):554-563.
70. Bayir H, Fadeel B, Palladino MJ, Witasz E, Kurnikov IV, Tyurina YY, Tyurin VA, Amoscato AA, Jiang J, Kochanek PM, et al: **Apoptotic interactions of cytochrome c: redox flirting with anionic phospholipids within and outside of mitochondria.** *Biochim Biophys Acta* 2006, **1757**(5-6):648-659.
71. Chapkin RS, Seo J, McMurray DN, Lupton JR: **Mechanisms by which docosahexaenoic acid and related fatty acids reduce colon cancer risk and inflammatory disorders of the intestine.** *Chem Phys Lipids* 2008, **153**(1):14-23.
72. Spydevold O, Bremer J: **Induction of peroxisomal beta-oxidation in 7800 C1 Morris hepatoma cells in steady state by fatty acids and fatty acid analogues.** *Biochim Biophys Acta* 1989, **1003**(1):72-79.
73. Smyth GK: **Linear models and empirical bayes methods for assessing differential expression in microarray experiments.** *Stat Appl Genet Mol Biol* 2004, **3**:Article 3.
74. Benjamini Y, Hochberg Y: **Controlling the false discovery rate: a practical and powerful approach to multiple testing.** *J R Stat Soc* 1995, **57**(1):289-300[http://www.ncbi.nlm.nih.gov/pubmed/16740248].

doi:10.1186/1476-511X-10-190

Cite this article as: Lundemo et al.: Tetradecylthioacetic acid inhibits proliferation of human SW620 colon cancer cells - gene expression profiling implies endoplasmic reticulum stress. *Lipids in Health and Disease* 2011 **10**:190.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

